Nasdaq

Lycia Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)CIK 0001806540South San Francisco, CaliforniaFilings at SEC EDGAR

At a glance

Most recent filing on October 30, 2026 — an open-market purchase by Venrock Healthcare Capital Partners III, L.P. on Oct 30, 2026.

We hold 29 Form 4 lines, going back to October 26, 2026.

Insider trades

How to read a Form 4

5 of 29 shown

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 29. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Venrock Healthcare Capital Partners III, L.P. 10% owner
$5,372Open-market buy
TradedOct 30, 2026FiledOct 30, 2026
Venrock Healthcare Capital Partners III, L.P. 10% owner
$231,281Open-market buy
TradedOct 30, 2026FiledOct 30, 2026
Venrock Healthcare Capital Partners III, L.P. 10% owner
$26,330Open-market buy
TradedOct 29, 2026FiledOct 30, 2026
Venrock Healthcare Capital Partners III, L.P. 10% owner
$115,047Open-market buy
TradedOct 28, 2026FiledOct 30, 2026
Venrock Healthcare Capital Partners III, L.P. 10% owner
$266,681Open-market buy
TradedOct 28, 2026FiledOct 30, 2026